News

Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.

The data from the phase II clinical trial of mRNA (LVRNA009) targeting Covid-19 - independently developed by AIM Vaccine, have been known to the public. The live virus-neutralizing antibodies tested by Wuhan Institute of Virology, CAS, revealed that, the geometric mean titer (GMT) of the live virus-neutralizing antibodies 14 days after full-course vaccination of mRNA, was 994.9 in the adult medium-dose group and 1405.7 in the adult high-dose group. These figures prove mRNA is fairly strong in immunogenicity. mRNA (LVRNA009), one of the earliest vaccines against Covid-19 with clinical trial permission, has got the top spot in advancing its clinical progress. It is significantly better than its counterparts in clinical effects.

Vice President and Chief Research Officer Zhang Fan, and General Manager of AIM Lifanda Peng Yucai, recently published the preclinical research data of the mRNA rabies vaccine LVRNA001 in the international authoritative academic journal "npj Vaccines": Only two vaccinations are needed to provide 100% safe and effective immune protection. This has laid a solid foundation for the next stage of research on human rabies mRNA vaccines.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA RSV (respiratory syncytial virus) vaccines has been submitted to the U.S. Food and Drug Administration (“FDA”) recently.

​Meningitis remains one of the most serious infectious diseases affecting children worldwide. It can progress rapidly, leading to severe complications such as brain damage, hearing loss, learning disabilities, or even death. The children meningitis vaccine plays a crucial role in preventing these outcomes by building early immunity against multiple strains of meningococcal bacteria.

​C-Type meningococcal disease is one of the most dangerous bacterial infections affecting the human nervous system, capable of progressing rapidly and causing severe complications or even death within hours if untreated. The C-Type meningitis vaccine is designed to protect against Neisseria meningitidis serogroup C, a major strain responsible for invasive meningococcal disease worldwide. This article provides a complete, in-depth exploration of the vaccine, including how it works, who needs it, safety considerations, global vaccination strategies, and practical insights for healthcare decision-making.